322
Views
8
CrossRef citations to date
0
Altmetric
Commentary

Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines

Pages 2447-2457 | Accepted 28 Jul 2009, Published online: 13 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Pieter-Jan Cortoos, Christa Gilissen, Gert Laekeman, Willy E. Peetermans, Hilde Leenaers, Luc Vandorpe & Steven Simoens. (2013) Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia. Scandinavian Journal of Infectious Diseases 45:3, pages 219-226.
Read now

Articles from other publishers (7)

Yanmin Guan & Yong Liu. (2020) Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. Medicine 99:25, pages e20648.
Crossref
Ping Xu, Hui Chen, Junchi Xu, Minjuan Wu, Xiaoyan Zhu, Fengping Wang, Sufang Chen & Junhua Xu. (2017) Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. International Journal of Infectious Diseases 60, pages 35-41.
Crossref
Ping Xu, Hui Chen, Junchi Xu, Minjuan Wu, Xiaoyan Zhu, Fengping Wang, Sufang Chen & Junhua Xu. (2015) WITHDRAWN: Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. International Journal of Infectious Diseases.
Crossref
Paul M. Tulkens, Pierre Arvis & Frank Kruesmann. (2012) Moxifloxacin Safety. Drugs in R&D 12:2, pages 71-100.
Crossref
Paul M. Tulkens, Pierre Arvis & Frank Kruesmann. (2012) Moxifloxacin Safety. Drugs in R&D 12:2, pages 71-100.
Crossref
Steven Simoens. (2011) Factors Affecting the Cost Effectiveness of Antibiotics. Chemotherapy Research and Practice 2011, pages 1-6.
Crossref
Mao Mao An, Zui Zou, Hui Shen, Ping Hui Gao, Yong Bing Cao & Yuan Ying Jiang. (2010) Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 36:1, pages 58-65.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.